2021 Archives - Ryvu Therapeutics

December 14, 2021

Ryvu announces option to license inflammation program exercised by Galapagos NV

Read More

December 13, 2021

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting and the 44th San Antonio Breast Cancer Symposium

Read More

November 10, 2021

Ryvu Therapeutics Reports Q3 2021 Financial Results

Read More

November 9, 2021

Ryvu Therapeutics to Highlight HPK1 and STING Programs at the Upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Read More

November 4, 2021

Ryvu Therapeutics & Collaborators to Present Clinical and Translational Data from RVU120 and SEL24/MEN1703 at the 63rd ASH Annual Meeting & Exposition and the 44th Annual SABCS

Read More

October 7, 2021

Ryvu Therapeutics co-runs Drug Discovery and Development MSc degree, at the Faculty of Pharmacy, Jagiellonian University

Read More

September 8, 2021

Ryvu Therapeutics Reports 2021 Half-Year Financial Results

Read More

August 25, 2021

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Read More

August 18, 2021

Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

Read More

August 3, 2021

Ryvu Therapeutics to participate in upcoming global investor conferences

Read More